Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% - Investors | Eli Lilly and Company
- Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% Investors | Eli Lilly and Company
- Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says CNN
- Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy MarketWatch
- Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial Bloomberg